| Mechanisms of resistance to immune checkpoint inhibitors |
159 |
| The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015 |
69 |
| Cytokines in clinical cancer immunotherapy |
69 |
| Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer |
63 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 |
62 |
| Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression |
58 |
| Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma |
50 |
| The clinical role of the TME in solid cancer |
43 |
| Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) |
37 |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC |
36 |
| Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy |
34 |
| Combining DNA damaging therapeutics with immunotherapy: more haste, less speed |
33 |
| Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer |
33 |
| The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention |
32 |
| Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma |
29 |
| Lipid metabolism in cancer cells under metabolic stress |
29 |
| Teaching an old dog new tricks: next-generation CAR T cells |
29 |
| The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS) |
28 |
| Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy |
28 |
| Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes |
27 |
| Cancer-associated fibroblasts-heroes or villains? |
27 |
| Harnessing the immune system in glioblastoma |
27 |
| The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores |
25 |
| Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR- an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study |
25 |
| VISTA expressed in tumour cells regulates T cell function |
24 |
| Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project |
23 |
| BRCA1/2 testing: therapeutic implications for breast cancer management |
23 |
| STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer |
22 |
| Tumour budding in oral squamous cell carcinoma: a meta-analysis |
22 |
| Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma |
22 |
| Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
21 |
| Ductal carcinoma in situ: to treat or not to treat, that is the question |
20 |
| MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis |
20 |
| Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy |
20 |
| Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer |
20 |
| A core matrisome gene signature predicts cancer outcome |
19 |
| Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4 |
19 |
| A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours |
19 |
| Targeting the Raf kinases in human cancer: the Raf dimer dilemma |
18 |
| S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies |
18 |
| Paracrine roles of cellular senescence in promoting tumourigenesis |
18 |
| A systematic review and quality assessment of individualised breast cancer risk prediction models |
18 |
| A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours |
18 |
| Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE- 006 |
17 |
| Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma |
17 |
| Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma |
17 |
| Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours |
17 |
| A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients |
17 |
| Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer |
17 |
| Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer |
17 |
